{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:23:13Z","timestamp":1789395793462,"version":"build-2803163510"},"reference-count":246,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011305","name":"The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["5P30CAO13148\\u201347"],"award-info":[{"award-number":["5P30CAO13148\\u201347"]}],"id":[{"id":"10.13039\/100011305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","award":["1R01CA294647"],"award-info":[{"award-number":["1R01CA294647"]}],"id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cytogfr.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T21:07:46Z","timestamp":1762463266000},"page":"203-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting cytokines: Reshaping the pancreatic tumor microenvironment"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-5503","authenticated-orcid":false,"given":"Dhana Sekhar Reddy","family":"Bandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva Chander","family":"Chabattula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasitha","family":"Pynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyous Thokkanatt","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Sarvesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101803","article-title":"Pancreatic ductal adenocarcinoma: emerging therapeutic strategies","volume":"43","author":"Osei-Bordom","year":"2022","journal-title":"Surg. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib4","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.3390\/ijerph20043640","article-title":"The rise of gastrointestinal cancers as a global phenomenon: unhealthy behavior or progress?","volume":"20","author":"Jardim","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"27","key":"10.1016\/j.cytogfr.2025.11.003_bib5","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: A review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib6","doi-asserted-by":"crossref","first-page":"1427802","DOI":"10.3389\/fonc.2024.1427802","article-title":"Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer","volume":"14","author":"Mustafa","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib7","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.3390\/ijms21093218","article-title":"Pancreatic cancer and its microenvironment\u2014recent advances and current controversies","volume":"21","author":"Stopa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/cancers16081589","article-title":"Targeted nanoparticle-based diagnostic and treatment options for pancreatic cancer","volume":"16","author":"Gu","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib10","first-page":"1","article-title":"Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells","author":"Wang","year":"2025","journal-title":"Cell Res."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.11.003_bib11","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.3390\/ijms252010991","article-title":"Inflammatory processes: key mediators of oncogenesis and Progression in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"25","author":"Yang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ccell.2024.03.005","article-title":"Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer","volume":"42","author":"Niu","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell death Dis."},{"issue":"14","key":"10.1016\/j.cytogfr.2025.11.003_bib14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.7150\/ijbs.25720","article-title":"Effect of stromal cells in tumor microenvironment on metastasis initiation","volume":"14","author":"Guo","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115622","article-title":"Microenvironmental regulation in tumor progression: interactions between cancer-associated fibroblasts and immune cells","volume":"167","author":"Gao","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s12967-025-06744-4","article-title":"Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117177","article-title":"The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds","volume":"178","author":"Bhol","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib20","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1002\/jcp.26518","article-title":"A multi-method evaluation of the effects of Inflammatory cytokines (IL-1\u03b2, IFN-\u03b3, TNF-\u03b1) on pancreatic \u03b2-cells","volume":"233","author":"Xie","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib21","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.21037\/tcr-24-679","article-title":"The mechanism of cytokine regulation of cancer occurrence and development in the tumor microenvironment and its application in cancer treatment: a narrative review","volume":"13","author":"Qu","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib23","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcb.2025.04.007","article-title":"Tumor\u2013stromal metabolic crosstalk in pancreatic cancer","author":"Thakur","year":"2025","journal-title":"Trends Cell Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/ijms25021009","article-title":"Navigating the cytokine seas: targeting cytokine signaling pathways in cancer therapy","volume":"25","author":"Stanilov","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/cam4.993","article-title":"Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhang","year":"2017","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317718403","article-title":"The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"39","author":"Park","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864739","article-title":"Dual relationship between stromal cells and immune cells in the tumor microenvironment","volume":"13","author":"Mun","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib31","article-title":"Interleukin-1 signaling in solid organ malignancies","volume":"1877","author":"Dosch","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA)Reviews Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.11.003_bib32","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.3390\/ijms22115421","article-title":"Inflammation-induced tumorigenesis and metastasis","volume":"22","author":"Hibino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.cytogfr.2025.11.003_bib33","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3390\/cells14191518","article-title":"Diverse Biological Processes Contribute to Transforming Growth Factor \u03b2-Mediated Cancer Drug Resistance","volume":"14","author":"Heiserman","year":"2025","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib34","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/biom10121666","article-title":"Transforming growth factor-\u03b2 signaling in fibrotic diseases and cancer-associated fibroblasts","volume":"10","author":"Shi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.matbio.2015.05.006","article-title":"The extracellular matrix and transforming growth factor-\u03b21: Tale of a strained relationship","volume":"47","author":"Hinz","year":"2015","journal-title":"Matrix Biol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib36","series-title":"Seminars in cancer biology","first-page":"499","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","author":"Bhatia","year":"2022"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib37","doi-asserted-by":"crossref","first-page":"1258538","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer gene Ther."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2023.10.003","article-title":"An emerging paradigm of CXCL12 involvement in the metastatic cascade","volume":"75","author":"Anastasiadou","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib45","series-title":"Seminars in cancer biology","first-page":"1105","article-title":"Multifaceted role of chemokines in solid tumors: From biology to therapy","author":"Raza","year":"2022"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.11.003_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/mmr.2024.13283","article-title":"Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma","volume":"30","author":"Li","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib48","series-title":"Targeting p38 MAPK Signaling to Suppress Inflammatory Tumor-Stroma-Immune Crosstalk in Pancreatic Cancer","author":"Singh","year":"2024"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","article-title":"The role of CXCL family members in different diseases","volume":"9","author":"Zhou","year":"2023","journal-title":"Cell death Discov."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib51","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.3390\/cancers14102446","article-title":"Role of cytokines and chemokines in angiogenesis in a tumor context","volume":"14","author":"Geindreau","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib52","doi-asserted-by":"crossref","first-page":"1371753","DOI":"10.3389\/fimmu.2024.1371753","article-title":"TGF-\u03b2, IL-1\u03b2, IL-6 levels and TGF-\u03b2\/Smad pathway reactivity regulate the link between allergic diseases, cancer risk, and metabolic dysregulations","volume":"15","author":"Elkoshi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2025.01.001","article-title":"Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ol.2022.13355","article-title":"Interferon-\u03b1 and its effects on cancer cell apoptosis","volume":"24","author":"Shi","year":"2022","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12032-024-02422-5","article-title":"Interleukin-6 serves as a critical factor in various cancer progression and therapy","volume":"41","author":"Mohamed","year":"2024","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/vaccines4030022","article-title":"The IL-8\/IL-8R axis: a double agent in tumor immune resistance","volume":"4","author":"David","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115267","article-title":"The role of IL-8 in cancer development and its impact on immunotherapy resistance","author":"Meier","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.cytogfr.2025.11.003_bib58","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.3390\/ijms26157326","article-title":"TGF-\u03b2 Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets","volume":"26","author":"Cecerska-Hery\u0107","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/jir.2014.0149","article-title":"Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy","volume":"35","author":"Bhattacharya","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib60","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/cancers13030564","article-title":"Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2021.03.005","article-title":"The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment","volume":"60","author":"Cardoso","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"52","key":"10.1016\/j.cytogfr.2025.11.003_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2416909121","article-title":"CXCL12 restricts tumor growth by suppressing the Ras, ERK1\/2, c-Myc, and the immune checkpoint PD-L1 pathways","volume":"121","author":"Kravtsova-Ivantsiv","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2025.03.001","article-title":"IL-1\u03b2+ macrophages and the control of pathogenic inflammation in cancer","author":"Caronni","year":"2025","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2023.06.006","article-title":"Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions","volume":"71","author":"Bandi","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"issue":"17","key":"10.1016\/j.cytogfr.2025.11.003_bib65","doi-asserted-by":"crossref","first-page":"9368","DOI":"10.3390\/ijms25179368","article-title":"Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis","volume":"25","author":"Gutierrez-Sainz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib66","first-page":"1","article-title":"Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer","author":"Shakiba","year":"2025","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib68","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/cancers14040995","article-title":"The immune landscape of human pancreatic ductal carcinoma: key players, clinical implications, and challenges","volume":"14","author":"Muller","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.11.003_bib70","article-title":"Transcriptome Landscape of Cancer-Associated Fibroblasts in Human PDAC","volume":"12","author":"Tao","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib71","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1051\/vcm\/2025005","article-title":"Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance","volume":"6","author":"Wang","year":"2025","journal-title":"Vis. Cancer Med."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib73","article-title":"Overcoming cancer treatment resistance: unraveling the role of cancer-associated fibroblasts","author":"Wang","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib74","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib76","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","article-title":"Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment","volume":"67","author":"Xiang","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib78","doi-asserted-by":"crossref","first-page":"598","DOI":"10.37349\/etat.2022.00103","article-title":"Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions","volume":"3","author":"Thiery","year":"2022","journal-title":"Explor. Target. AntiTumor Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib80","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12967-025-06306-8","article-title":"Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib82","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155832","article-title":"Interleukin-6 classic and trans-signaling utilize glucose metabolism reprogramming to achieve anti-or pro-inflammatory effects","volume":"155","author":"Xu","year":"2024","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1272\/jnms.77.97","article-title":"Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase\/fructose-2, 6-bisphosphatase-3","volume":"77","author":"Ando","year":"2010","journal-title":"J. Nippon Med. Sch."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/cells10030653","article-title":"Annexin A1 expression is associated with Epithelial\u2013Mesenchymal Transition (EMT), cell proliferation, prognosis, and drug response in pancreatic cancer","volume":"10","author":"Oshi","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib87","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib88","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.bbalip.2014.06.007","article-title":"Fatty acid oxidation is dispensable for human macrophage IL-4-induced polarization","volume":"1841","author":"Namgaladze","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA)Molecular Cell Biology Lipids"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib89","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/0008-5472.CAN-22-2316","article-title":"Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell\u2013derived cytokines","volume":"83","author":"Schw\u00f6rer","year":"2023","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib90","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41419-021-04391-3","article-title":"Reciprocal regulation of LOXL2 and HIF1\u03b1 drives the Warburg effect to support pancreatic cancer aggressiveness","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib91","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","article-title":"Tumor\u2013stroma IL1\u03b2-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.cytogfr.2025.11.003_bib92","doi-asserted-by":"crossref","first-page":"14652","DOI":"10.3390\/ijms241914652","article-title":"Differential effects of pancreatic cancer-derived extracellular vesicles driving a suppressive environment","volume":"24","author":"Purushothaman","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib93","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78921","article-title":"Neutrophil-mediated fibroblast-tumor cell il-6\/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study","volume":"11","author":"de Castro Silva","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215722","article-title":"Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model","volume":"539","author":"Li","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216784","article-title":"Tumor-associated macrophages drive glycolysis through the IL-8\/STAT3\/GLUT3 signaling pathway in pancreatic cancer progression","volume":"588","author":"Zhong","year":"2024","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib96","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/0008-5472.CAN-15-1293","article-title":"TGF\u03b2 signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis","volume":"76","author":"Principe","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib97","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","article-title":"Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs, and Foxp3+ cancer cells in locally advanced pancreatic cancer","volume":"29","author":"Boucher","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib98","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/2326-6066.CIR-23-1073","article-title":"Blockade of IL1\u03b2 and PD1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor","volume":"12","author":"Oberstein","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.11.003_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163022","article-title":"Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer","volume":"8","author":"Kitamura","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI187024","article-title":"Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Sun","year":"2025","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib101","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","article-title":"Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib102","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10637-018-0580-2","article-title":"Ruxolitinib+ capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies","volume":"36","author":"Hurwitz","year":"2018","journal-title":"Investig. N. Drugs"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib103","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1535-7163.MCT-22-0055","article-title":"IDO1 is a therapeutic target for pancreatic cancer\u2013associated depression","volume":"21","author":"Hue","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib104","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-022-01538-4","article-title":"Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis","volume":"21","author":"Qi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107610","article-title":"The multiple roles of the IAP super-family in cancer","volume":"214","author":"Kumar","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.11.003_bib106","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7150\/jca.28229","article-title":"Prognostic value of XIAP level in patients with various cancers: a systematic review and meta-analysis","volume":"10","author":"Gao","year":"2019","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3892\/mco.2013.58","article-title":"XIAP expression is associated with pancreatic carcinoma outcome","volume":"1","author":"Li","year":"2013","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib108","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib109","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.11.003_bib110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.cytogfr.2025.11.003_bib111","article-title":"MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3","volume":"23","author":"Lin","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib112","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/carcin\/bgt394","article-title":"Combined inhibition of Notch and JAK\/STAT is superior to monotherapies and impairs pancreatic cancer progression","volume":"35","author":"Palagani","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib113","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2015.10.057","article-title":"Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib","volume":"52","author":"Nagaraju","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107274","article-title":"Riboflavin protects against pancreatic cancer metastasis by targeting TGF-\u03b2 receptor 1","volume":"146","author":"Zhao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"21","key":"10.1016\/j.cytogfr.2025.11.003_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.182766","article-title":"III, Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-\u03b2 depletion","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.455","article-title":"Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGF\u03b2 and JNK\/AP-1","volume":"8","author":"Liu","year":"2017","journal-title":"Cell death Dis."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-\u03b2 receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.gastro.2024.02.046","article-title":"Targeting ESE3\/EHF with Nifurtimox inhibits CXCR2+ neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy","volume":"167","author":"Xie","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216185","article-title":"Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer","volume":"563","author":"Prajapati","year":"2023","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib120","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The role of immunotherapy in pancreatic cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib121","article-title":"Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4\/PD-1 inhibition in models of pancreatic ductal adenocarcinoma","author":"Raufi","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib122","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000308","article-title":"Interferon gamma inhibits CXCL8\u2013CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib123","doi-asserted-by":"crossref","first-page":"1578870","DOI":"10.3389\/fimmu.2025.1578870","article-title":"Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib124","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17\u2013induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib125","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib126","article-title":"Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer","author":"Mahadevan","year":"2025","journal-title":"bioRxiv"},{"issue":"24","key":"10.1016\/j.cytogfr.2025.11.003_bib127","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1158\/0008-5472.CAN-24-0830","article-title":"Combined autophagy Inhibition and dendritic cell recruitment induces antitumor immunity and enhances immune checkpoint Blockade sensitivity in pancreatic cancer","volume":"84","author":"Oyama","year":"2024","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/2326-6066.CIR-22-0398","article-title":"IL18 receptor signaling regulates tumor-reactive CD8+ T-cell exhaustion via activation of the IL2\/STAT5\/mTOR pathway in a pancreatic cancer model","volume":"11","author":"Lutz","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib129","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","article-title":"The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer","volume":"39","author":"Freed-Pastor","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.11.003_bib130","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910515","article-title":"Targeting TGF \u03b2R2-mutant tumors exposes vulnerabilities to stromal TGF \u03b2 blockade in pancreatic cancer","volume":"11","author":"Huang","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib131","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215751","article-title":"Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis","volume":"548","author":"He","year":"2022","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib133","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/cbr.2022.0045","article-title":"IL-6 accelerates the proliferation and metastasis of pancreatic cancer cells via the miR-455-5p\/IGF-1R Axis","volume":"39","author":"Zhang","year":"2024","journal-title":"Cancer Biotherapy Radiopharm."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107752","article-title":"The pro-inflammatory cytokines IL-1\u03b2 and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cancer cells","volume":"300","author":"Silva","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.11.003_bib135","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","article-title":"Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.11.003_bib136","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-23-0547","article-title":"Lorazepam stimulates IL6 production and is associated with poor survival outcomes in pancreatic cancer","volume":"29","author":"Cornwell","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib137","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-019-0483-9","article-title":"ZEB1 and IL-6\/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins","volume":"121","author":"Al-Ismaeel","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib138","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1568009618666180430123939","article-title":"Blocking IL-6\/GP130 signaling inhibits cell viability\/proliferation, glycolysis, and colony forming activity in human pancreatic cancer cells","volume":"19","author":"Chen","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib139","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers12071791","article-title":"Interleukin-1\u03b2 and cancer","volume":"12","author":"R\u00e9b\u00e9","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib140","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1053\/j.gastro.2008.06.078","article-title":"Overexpression of interleukin-1\u03b2 in the murine pancreas results in chronic pancreatitis","volume":"135","author":"Marrache","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib141","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-16-1121","article-title":"Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib142","first-page":"910","article-title":"Autocrine production of interleukin 1\u03b2 confers constitutive nuclear factor \u03baB activity and chemoresistance in pancreatic carcinoma cell lines","volume":"62","author":"Arlt","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib143","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00063-004-1027-4","article-title":"Autokrine IL-1\u03b2-Sekretion f\u00fchrt zu erh\u00f6hter NF-\u03baB-Aktivit\u00e4t und zu Chemoresistenz in Pankreaskarzinomzellen in vivo","volume":"99","author":"M\u00fcerk\u00f6ster","year":"2004","journal-title":"Med. Klin."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib144","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","article-title":"Tumor cell\u2013derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer","volume":"80","author":"Das","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib145","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41416-022-01927-y","article-title":"ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour\u2013stromal IL-1\u03b2\/NF\u2013\u03baB\/ESE3 signalling axis","volume":"127","author":"Zhao","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"7986","key":"10.1016\/j.cytogfr.2025.11.003_bib146","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-025-00607-w","article-title":"Distinct response to IL-1\u03b2 blockade in liver-and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216403","article-title":"FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3\/IL-1\u03b2 axis","volume":"575","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.11.003_bib149","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41388-023-02647-0","article-title":"The platelet pannexin 1-IL-1\u03b2 axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis","volume":"42","author":"Li","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.21037\/jgo-21-910","article-title":"LRG1 in pancreatic cancer cells promotes inflammatory factor synthesis and the angiogenesis of HUVECs by activating VEGFR signaling","volume":"13","author":"Cai","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.11.003_bib151","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s43018-021-00258-w","article-title":"TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer","volume":"2","author":"Tu","year":"2021","journal-title":"Nat. Cancer"},{"issue":"22","key":"10.1016\/j.cytogfr.2025.11.003_bib152","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153242","article-title":"Targeting TNF-\u03b1\u2013producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling","volume":"7","author":"Dixit","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247550","article-title":"Treatment of 13-cis retinoic acid and 1, 25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells","volume":"16","author":"Cheng","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib154","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41419-021-03920-4","article-title":"TNF-\u03b1 induces endothelial\u2013mesenchymal transition promoting stromal development of pancreatic adenocarcinoma","volume":"12","author":"Adjuto-Saccone","year":"2021","journal-title":"Cell death Dis."},{"issue":"16","key":"10.1016\/j.cytogfr.2025.11.003_bib155","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.18632\/aging.204941","article-title":"TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-\u03baB signaling pathway","volume":"15","author":"Gao","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib156","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.cytogfr.2025.11.003_bib157","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.7150\/jca.15786","article-title":"Hedgehog signaling non-canonical activated by pro-inflammatory cytokines in pancreatic ductal adenocarcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib158","doi-asserted-by":"crossref","first-page":"2457761","DOI":"10.1080\/15384047.2025.2457761","article-title":"miR-301a-mediated crosstalk between the Hedgehog and HIPPO\/YAP signaling pathways promotes pancreatic cancer","volume":"26","author":"Qi","year":"2025","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228015","article-title":"Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5","volume":"15","author":"Ando","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib160","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41467-024-50450-6","article-title":"Necroptosis enhances \u2018don\u2019t eat me\u2019signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis","volume":"15","author":"Liao","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.11.003_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib162","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00262-025-03946-z","article-title":"Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone","volume":"74","author":"Yagi","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib163","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/s41598-020-62416-x","article-title":"Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes","volume":"10","author":"Pausch","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12307-019-00223-3","article-title":"Cancer-associated fibroblasts enhance survival and progression of the aggressive pancreatic tumor via FGF-2 and CXCL8","volume":"12","author":"Awaji","year":"2019","journal-title":"Cancer Microenviron."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/jir.2018.0070","article-title":"Interferon gamma inhibits CXCL8-induced proliferation and migration of pancreatic cancer BxPC-3 cell line via a RhoGDI2\/Rac1\/NF-\u03baB signaling pathway","volume":"38","author":"Zhang","year":"2018","journal-title":"J. Interferon Cytokine Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib166","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ijc.24040","article-title":"CXCL8\/IL-8 and CXCL12\/SDF-1\u03b1 co-operatively promote invasiveness and angiogenesis in pancreatic cancer","volume":"124","author":"Matsuo","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib167","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-023-01721-z","article-title":"Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis","volume":"9","author":"Huang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib168","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-23-0240","article-title":"Tumor explants elucidate a cascade of paracrine SHH, WNT, and VEGF signals driving pancreatic cancer angiosuppression","volume":"14","author":"Hasselluhn","year":"2024","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib169","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-23-1660","article-title":"Transfer learning reveals cancer-associated fibroblasts are associated with epithelial\u2013mesenchymal transition and inflammation in cancer cells in pancreatic ductal adenocarcinoma","volume":"84","author":"Guinn","year":"2024","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.cytogfr.2025.11.003_bib170","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70446","article-title":"Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR-378a-3p\/VEGFA\/RGC-32 Axis","volume":"13","author":"He","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib171","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1038\/s41467-022-33991-6","article-title":"PD-L1-directed PlGF\/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib172","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib173","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ijrobp.2020.11.053","article-title":"Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: a phase 1 study","volume":"109","author":"Van Limbergen","year":"2021","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib174","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.637","article-title":"Randomized phase III study of FOLFOX alone and with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer (SEQUOIA)","author":"Hecht","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib176","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.hpb.2017.01.012","article-title":"Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up","volume":"19","author":"Ohman","year":"2017","journal-title":"HPB"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib177","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"19","key":"10.1016\/j.cytogfr.2025.11.003_bib178","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF\u2013transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib179","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib180","doi-asserted-by":"crossref","first-page":"1476644","DOI":"10.3389\/fimmu.2025.1476644","article-title":"Current status of cytokine-induced killer cells and combination regimens in breast cancer","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib181","series-title":"Cancer Immunology: Bench to Bedside Immunotherapy of Cancers","first-page":"169","article-title":"Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers","author":"Malvicini","year":"2020"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib182","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib183","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae267","article-title":"Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate","volume":"30","author":"Moini","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib184","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e15750","article-title":"A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients","author":"Whiteley","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib185","article-title":"Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC), American Society","author":"Becerra","year":"2018","journal-title":"Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib186","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/2159-8290.CD-22-1013","article-title":"Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer","volume":"13","author":"Wan","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib187","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01631","article-title":"Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7756","key":"10.1016\/j.cytogfr.2025.11.003_bib188","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib189","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib190","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/MPA.0b013e318279b87f","article-title":"Disrupting cytokine signaling in pancreatic cancer: a phase I\/II study of etanercept in combination with gemcitabine in patients with advanced disease","volume":"42","author":"Wu","year":"2013","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib191","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191422","article-title":"Targeting lactylation and the STAT3\/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib192","first-page":"OF1","article-title":"Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer","author":"Grierson","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib193","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib194","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (CC motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Investig. N. Drugs"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib195","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coph.2009.06.011","article-title":"Inflammation and pancreatic cancer: an evidence-based review","volume":"9","author":"Greer","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib196","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00280-019-03807-4","article-title":"TGF\u03b2 receptor inhibitor galunisertib is linked to inflammation-and remodeling-related proteins in patients with pancreatic cancer","volume":"83","author":"Melisi","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib197","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2020.03.005","article-title":"Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma","volume":"132","author":"O'Reilly","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib198","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clnesp.2019.06.003","article-title":"The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study","volume":"33","author":"Akita","year":"2019","journal-title":"Clin. Nutr. ESPEN"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2017-0665","article-title":"A phase Ib\/II study of the JAK1 inhibitor, itacitinib, plus nab-paclitaxel and gemcitabine in advanced solid tumors","volume":"24","author":"Beatty","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib200","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4147","article-title":"Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti\u2013PD-L1 NK cell therapy more than doubles historical overall survival in patients with third-to sixth-line advanced pancreatic cancer","author":"Seery","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib201","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/cancers13040697","article-title":"Targeting and reprograming cancer-associated fibroblasts and the tumor microenvironment in pancreatic cancer","volume":"13","author":"Sunami","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib202","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011404","article-title":"IL-1\u03b2 blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","volume":"13","author":"Talele","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib203","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS626","article-title":"Phase Ib\/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer","author":"Akce","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib204","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.cytogfr.2025.11.003_bib205","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3\u2013CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib206","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/07357907.2021.1977314","article-title":"Surgical trauma-induced CCL2 upregulation mediates lung cancer progression by promoting treg recruitment in mice and patients","volume":"40","author":"Zhao","year":"2022","journal-title":"Cancer Investig."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib207","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J. Hepatol."},{"issue":"2-3","key":"10.1016\/j.cytogfr.2025.11.003_bib208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.imlet.2003.12.009","article-title":"Impact of tumor-derived CCL2 on T cell effector function","volume":"91","author":"Vitiello","year":"2004","journal-title":"Immunol. Lett."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.11.003_bib209","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41419-020-03208-z","article-title":"Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome bevacizumab resistance in ETV5+ colorectal cancer","volume":"11","author":"Feng","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12865-022-00493-5","article-title":"Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb\/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy","volume":"23","author":"Bess","year":"2022","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib211","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-010-0473-5","article-title":"Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy","volume":"104","author":"Zhu","year":"2011","journal-title":"J. Neuro Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.11.003_bib212","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10585-012-9473-5","article-title":"Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models","volume":"29","author":"Zollo","year":"2012","journal-title":"Clin. Exp. Metastas.."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib213","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molimm.2019.02.014","article-title":"RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment","volume":"109","author":"Mu","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib214","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fonc.2019.00231","article-title":"CCL2\/CCR2 axis promotes the progression of salivary adenoid cystic carcinoma via recruiting and reprogramming the tumor-associated macrophages","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib215","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1073\/pnas.1910856117","article-title":"CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas","volume":"117","author":"Flores-Toro","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib216","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","article-title":"Disruption of SLFN11 deficiency\u2013induced CCL2 signaling and macrophage M2 polarization potentiates anti\u2013PD-1 therapy efficacy in hepatocellular carcinoma","volume":"164","author":"Zhou","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib217","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib218","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.730","article-title":"Nivolumab and a CCR2\/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: results of phase I study","author":"Christenson","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"13_ement","key":"10.1016\/j.cytogfr.2025.11.003_bib219","doi-asserted-by":"crossref","first-page":"CT124","DOI":"10.1158\/1538-7445.AM2018-CT124","article-title":"Abstract CT124: A phase Ib\/II study of BMS-813160, a CC chemokine receptor (CCR) 2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer","volume":"78","author":"Le","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.11.003_bib220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tips.2014.02.003","article-title":"Targeting CCR4 as an emerging strategy for cancer therapy and vaccines","volume":"35","author":"Bayry","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.11.003_bib221","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1175794","article-title":"Cancer cell-derived IL-1\u03b1 induces CCL22 and the recruitment of regulatory T cells","volume":"5","author":"Wiedemann","year":"2016","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.cytogfr.2025.11.003_bib222","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","article-title":"Oncogenic BRAFV600E governs regulatory T-cell recruitment during melanoma tumorigenesis","volume":"78","author":"Shabaneh","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib223","first-page":"900","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"TJ","year":"2004","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib224","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","article-title":"CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer","volume":"7","author":"Maeda","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.11.003_bib225","first-page":"4853","article-title":"A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens, Blood","volume":"118","author":"Pere","year":"2011","journal-title":"J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib226","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.11.003_bib227","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14728222.2014.949238","article-title":"The potential to target CCL5\/CCR5 in breast cancer","volume":"18","author":"Velasco-Vel\u00e1zquez","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.11.003_bib228","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib229","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007939","article-title":"CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value","volume":"12","author":"Battaglin","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib230","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1215\/S1152851704001061","article-title":"The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis","volume":"7","author":"Brat","year":"2005","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.11.003_bib231","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib232","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib233","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS631","article-title":"A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma","author":"Dunne","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.11.003_bib234","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/cas.16205","article-title":"LAG-3: recent developments in combinational therapies in cancer","volume":"115","author":"Chavanton","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156344","article-title":"Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: A breast cancer and glioblastoma view","volume":"170","author":"Gon\u00e7alves","year":"2023","journal-title":"Cytokine"},{"issue":"17","key":"10.1016\/j.cytogfr.2025.11.003_bib236","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 axis in tumor immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.11.003_bib237","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12032-022-01935-1","article-title":"Breast tumor metastasis following filgrastim administration due to the SDF-1\/CXCR4 pathway","volume":"40","author":"Khalighfard","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib238","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopha.2015.01.020","article-title":"Downregulation of the CXCR4\/CXCL12 axis blocks the activation of the Wnt\/\u03b2-catenin pathway in human colon cancer cells","volume":"71","author":"Song","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib239","series-title":"Seminars in cancer biology","first-page":"176","article-title":"The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies","author":"Daniel","year":"2020"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib240","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3389\/fimmu.2018.03018","article-title":"Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer","volume":"9","author":"Eckert","year":"2018","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.11.003_bib241","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","article-title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment","volume":"149","author":"Bao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.11.003_bib242","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cytogfr.2025.11.003_bib243","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4200","article-title":"CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (CXC) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-na\u00efve pancreas adenocarcinoma","author":"Manji","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib244","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS533","article-title":"A pilot study to assess the efficacy, safety, and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer","author":"Fogelman","year":"2018","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.003_bib245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS530","article-title":"MORPHEUS: A phase Ib\/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer","author":"Manji","year":"2018","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.11.003_bib246","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ijc.25449","article-title":"Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras","volume":"128","author":"Wed\u00e9n","year":"2011","journal-title":"Int. J. Cancer"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:31:10Z","timestamp":1781235070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":246,"alternative-id":["S1359610125001455"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.11.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cytokines: Reshaping the pancreatic tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}